Researches

New drug outperforms PreP in preventing HIV among African women

The Joint United Nations Programme on HIV/AIDS (UNAIDS) has announced that it is strongly encouraged by new study results showing that the antiretroviral medicine cabotegravir, which is administered by injection every two months, prevents HIV among women. The study shows that the long-acting injections among women in sub-Saharan Africa were 89% more efficient in preventing HIV compared to daily tablets of pre-exposure prophylaxis (PrEP). “These results are hugely significant. UNAIDS has long been calling for additional, acceptable and effective HIV prevention options

There is a promising vaccine candidate for herpes

A genetically edited form of a herpes simplex virus — rewired to keep it from taking refuge in the nervous system and eluding an immune response — has outperformed a leading vaccine candidate in a new study from the University of Cincinnati, Northwestern University and the University of Nebraska-Lincoln. Published Nov. 6 in the journal Nature Vaccines, the study found that vaccinating guinea pigs with the modified live virus significantly increased the production of virus-combating antibodies. When challenged with a virulent strain

Drugs for HIV, hepatitis could prevent type 2 diabetes – study

A group of drugs used to treat HIV and hepatitis B could be repurposed to prevent type 2 diabetes, a new study suggests. Researchers found that patients taking the drugs had a 33% lower risk of developing diabetes. The scientists say that the risk reduction makes sense based on how the drugs are known to work, and noted that one of the drugs, lamivudine, improved insulin sensitivity significantly in human cell samples and in a mouse model of diabetes. (In type